TD Waterhouse Canada’s BioMarin Pharmaceuticals BMRN Stock Holding History

TD Waterhouse Canada’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-973	Closed	-$84.5K	–	1922
2024 Q1	$84.5K	Hold	973	–	–	﹤0.01%	941
2023 Q4	$95.1K	Buy	+973	New	+$86.1K	﹤0.01%	817
2023 Q2	–	Sell	-10	Closed	-$1.3K	–	1764
2023 Q1	$1.3K	Buy	+10	New	+$1.04K	﹤0.01%	1567
2022 Q4	–	Sell	-600	Closed	-$52K	–	1706
2022 Q3	$52K	Hold	600	–	–	﹤0.01%	899
2022 Q2	$51K	Sell	600 -13	-2%	-$1.03K	﹤0.01%	917
2022 Q1	$48.6K	Buy	613 +13	+2%	+$1.09K	﹤0.01%	1001
2021 Q4	$52.3K	Buy	+600	New	+$49.5K	﹤0.01%	997

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

TD Waterhouse Canada's BMRN Position: Q2 2024 in Review

TD Waterhouse Canada sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 973 shares — an estimated $84.5K sold.

TD Waterhouse Canada first reported a position in BMRN in Q4 2021 and held it in 7 quarters. The position peaked at $95.1K in Q4 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

TD Waterhouse Canada reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
TD Waterhouse Canada sold 973 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $84.5K.
TD Waterhouse Canada first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 7 quarters.
TD Waterhouse Canada's BioMarin Pharmaceuticals position peaked at $95.1K in Q4 2023.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on TD Waterhouse Canada's 13F filing for Q2 2024, filed 2 Aug 2024.